FDA to Offer Bonuses for Speedy Drug Reviews

New pilot program aims to recognize and reward efficient FDA staff, but raises concerns over potential quality trade-offs.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

The head of the Food and Drug Administration plans to start offering bonus payments to agency drug reviewers who complete their work ahead of schedule, in a bid to boost efficiency and address staffing challenges. However, the program raises questions about whether it could lead to rushed reviews and undermine public trust in the FDA's independence.

Why it matters

The FDA's drug review process is critical for ensuring the safety and efficacy of new medications, but has long been criticized as too slow. This new bonus program is an attempt to address staffing shortages and speed up approvals, but there are concerns it could compromise the rigor of the review process and further erode public perception of the FDA's objectivity.

The details

FDA Commissioner Marty Makary announced the new pilot program, which will offer quarterly bonus payments to employees who complete drug reviews ahead of schedule. The payments will be based on 'weighted time savings' and assessments of work quality and complexity. However, the program excludes some FDA staff like factory inspectors who are not directly involved in drug reviews. There are also concerns the bonuses could create ethical dilemmas if reviewers are seen as being rewarded for rushing safety and efficacy confirmations.

  • The first quarterly bonus payments are expected to start around August 2026.
  • The FDA has collected user fees from drug companies since the 1990s to help pay for faster reviews, but has never before offered direct bonuses to employees for meeting or exceeding review timelines.

The players

Marty Makary

The commissioner of the Food and Drug Administration who announced the new bonus program.

Robert F. Kennedy Jr.

The Health Secretary who has described FDA staffers as 'a sock puppet' of the pharmaceutical industry.

Dr. Vinay Prasad

The FDA's chief scientist and vaccine director who has personally overruled staff in rejecting some experimental therapies and biotech drugs.

Got photos? Submit your photos here. ›

What they’re saying

“FDA staffers as 'a sock puppet' of industry since becoming the nation's top health official last February.”

— Robert F. Kennedy Jr., Health Secretary (AP)

What’s next

The FDA will begin offering the first quarterly bonus payments to eligible employees around August 2026.

The takeaway

The FDA's new bonus program for speedy drug reviews aims to boost efficiency, but raises concerns that it could undermine the rigor of the review process and further erode public trust in the agency's independence from the pharmaceutical industry.